|
Glaxo Smith Kline has had successful overseas clinical trials of lapatinib as a first-line therapy for HER2 B/C, as well as other trials for use in HER2 B/C that has progressed after standard chemotherapy and Herceptin. I don't understand why they are delaying seeking FDA approval until late 2006 or 2007. I know we all get frustrated as we cling to hope of the next miracle treatment, but this is really discouraging. It's hard to sit around reading the promising study abstracts, while your loved one gets sicker and sicker.
|
Threaded Mode